Article Details
Retrieved on: 2024-04-27 10:50:33
Tags for this article:
Click the tags to see associated articles and topics
Summary
Pfizer's newly FDA-approved haemophilia B gene therapy, BEQVEZ, offers a one-time treatment alternative to ongoing intravenous FIX infusions, with the aim of improving patient quality of life and reducing treatment burden.
Article found on: www.tipranks.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here